Learn more about our Diagnostics work.
“Game-changing” testing innovation from Quidel will save lives heading into flu season WASHINGTON, D.C. – AdvaMed® released the following statements on the announcement last night that Quidel Corporation, a member company of AdvaMed®…
WASHINGTON, D.C. – New data from AdvaMed®’s COVID-19 Diagnostic Supply Registry reveals that total U.S. shipments of COVID-19 molecular diagnostic tests have reached 160 million. A breakdown of the data shows…
100-million-plus antigen tests to be shipped by end of fall WASHINGTON, D.C. – The Advanced Medical Technology Association® (AdvaMed®) today announced that total U.S. shipments of COVID-19 molecular diagnostic tests have…
WASHINGTON, D.C. – AdvaMed® President and CEO Scott Whitaker released the following statement: “AdvaMed® fully supports policies that foster innovation and regulatory flexibility to speed quality tests to patients. This principle…
WASHINGTON, D.C. – AdvaMed® President and CEO Scott Whitaker released the following statement:
Read background information on how AdvaMedDx®’s members produce IVD tests to detect COVID-19.
WASHINGTON, D.C. – The Advanced Medical Technology Association® (AdvaMed®) today announced that total U.S. shipments of COVID-19 molecular diagnostic tests reached approximately 100 million, as of July 25, based on the latest…
Unequal access to medical technologies and, more broadly, health care services continues to persist – often disproportionately impacting the lives of racial and ethnic minorities.
AdvaMed® announced that shipments of COVID-19 molecular diagnostic tests reached one million per day for the week ending July 24, based on the latest data from the association’s National Testing Registry.
Whitaker Calls National Registry “Crucial Tool” for Federal, State Authorities; Announces More Than 65 Million Tests Shipped Nationwide Since Beginning of Pandemic WASHINGTON, D.C. – In its latest action to help ensure…